Noxopharm Limited (NOX.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.049 (+0.00%) as of
Key statistics
- Market cap
- 15.05M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0490 – 0.1100
- Beta
- 0.13
- Revenue (TTM)
- 1.43M
- Profit margin
- 0.00%
- Volume
- 5.54k
About Noxopharm Limited
Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region. The company develops Sofra, a platform designed to regulate innate immune signaling with greater precision; and Chroma, a small molecule technology platform focused on the development of multiple drug candidates for cancer treatment. It is also developing SOF-SKN, a topical therapy that has completed Phase I clinical trial for cutaneous lupus erythematosus; and CRO-67, a dual-cell preclinical drug candidate for the treatment of pancreatic cancer. In addition, the company intends to improve mRNA vaccines. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Glenhaven, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.